Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 16/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25547252 | 0.84 | GRIN2B (0.41) | GRIN2BGRIN1 | |
| SCHEMBL25544881 | 0.78 | KDM4E (0.54) | PIK3C3GRIN2BKDM4EKMT2A | |
| SCHEMBL25544941 | 0.77 | IKBKE (0.50) | PIK3C3GRIN2BGRIN1DAOKDM4E | |
| SCHEMBL25544916 | 0.73 | PIK3C3 (0.44) | PIK3C3KDM4EKMT2A | |
| SCHEMBL25544923 | 0.73 | CHEK2 (0.55) | PIK3C3 | |
| SCHEMBL612856 | 0.73 | KDM4E (0.48) | PIK3C3KDM4EKMT2A | |
| SCHEMBL20049804 | 0.72 | GRIN2B (0.44) | GRIN2BGRIN1SLC6A7 | |
| SCHEMBL2322786 | 0.72 | LDHA (0.54) | PIK3C3 | |
| SCHEMBL22106314 | 0.72 | DAO (0.52) | DAOKDM4EKMT2A | |
| SCHEMBL11009661 | 0.72 | DAO (0.41) | GRIN2BGRIN1DAOKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | PIK3C3 478/4885GRIN2B 3212/4885GRIN1 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.